A common IRF7 lupus-risk haplotype also strengthens the antiviral interferon response
A study announced by Cincinnati Children's finds that a common lupus-risk haplotype around IRF7, the transcription factor that helps launch the antiviral interferon response, increases IRF7-dependent production of alpha interferon. Science reports the same core development: a common gene variant that raises lupus risk may also strengthen antiviral defence. The hospital says the result does not change how lupus is diagnosed or treated, and it gives no figure for how common the haplotype is.
Science··Night
A haplotype around IRF7 raised alpha interferon
Cincinnati Children's research bulletin reports a study published on 11 September 2026 in The American Journal of Human Genetics. A team led by Leah Kottyan, Matthew Weirauch and Stephen Waggoner examined a common lupus-risk haplotype linked to IRF7, interferon regulatory factor 7, a transcription factor at the centre of the antiviral response. The haplotype increased IRF7-dependent induction of alpha interferon under the conditions studied. Science reports the same principal development: a common gene variant that increases the risk of lupus may also protect against viruses.[1], [2]
The same interferon path is implicated in lupus
Type I interferon signalling is also strongly implicated in lupus, and many patients carry chronically elevated interferon activity, sometimes called an interferon signature. Cincinnati Children's presents the shared biology as a trade-off: a stronger antiviral response in one setting, and a greater tendency for the immune system to turn on the body's own tissues in another. The hospital treats that evolutionary reading as a proposed explanation of why the haplotype remains common, leaving it uncertain whether the variant provided a historical survival advantage or if its prevalence resulted from genetic drift, since the study does not demonstrate a selection result directly. Science covers the same core event as a gene variant that both raises lupus risk and may strengthen antiviral defence.[1], [2]
No change to diagnosis or treatment
Cincinnati Children's says the finding brings no immediate change to how lupus is diagnosed or treated, and carrying the haplotype does not mean that a person will develop the disease. Lupus arises from many genetic variants together with environmental exposures and other biological factors. The bulletin gives no figure for how frequent the haplotype is in populations. First author Sam Virolainen, a graduate of the Immunology Graduate Program, says the work aims to explain how a lupus-linked variant affects the immune system more broadly, not only that one disease.[1]
